Equip F vet.
Active substance
ATC code
Species
Horses.
Indications
For the active immunisation of horses of 5 months of age or older against Equine
Influenza of H7N7 and H3N8 types (European or American strains, including Florida sublineage Clade 1 and Clade 2 isolates) to reduce clinical signs and virus excretion after infection.
Onset of immunity: within 2 weeks of completion of the primary course Duration of immunity: 15 months.
Dose to be administered and administration route
Dose: 2 ml.
Administration: Equip F should be shaken thoroughly before use, and administered by deep intramuscular injection.
Vaccination schedule: For protection against quine influenza, Equip F should be used as follows:
|
Primary Course |
First dose |
EQUIP F 6 week interval |
|
|
Second dose |
EQUIP F 5 month interval |
|
Boosters |
1st booster |
EQUIP F 12-15 month interval |
|
2nd and subsequent boosters |
|
EQUIP F 12-15 month intervals |
Note: The routine practice of administering booster doses annually may remain the most convenient, even though protection against equine influenza has been demonstrated by challenge studies 15 months following the third vaccination (first booster dose). No field challenge studies have been carried out prior to the third vaccination; instead efficacy was evaluated by serology which showed titres equivalent to those found in horses protected against challenge at 15 months. It is recommended that a single booster dose should only be administered to horses that have already received a full primary course using vaccines that contain the same types of equine influenza virus included in this vaccine. A full primary course may be considered necessary in horses that have not been suitably primed.
Adverse reactions
Horses.
|
Rare (1 to 10 animals / 10,000 animals treated): |
Injection site swelling1,3 Stiffness1 Elevated temperature1, 2 |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Injection site pain Hypersensitivity reaction4 Anorexia, Lethargy |
1 This condition normally resolves by the day following vaccination.
2 Mild, transient, typically 9-12 hours post vaccination.
3 Local, small (10-20 mm in diameter), soft, non-painful.
4 In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
